Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Type I error control and interim monitoring for co-primary hypotheses involving a subgroup in the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) trial

Contemporary Clinical Trials Communications(2025)10.1016/j.conctc.2025.101592Source: DataRank Database

Type I error control and interim monitoring for co-primary hypotheses involving a subgroup in the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) trial is a research paper published in Contemporary Clinical Trials Communications (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.00)OA: goldTopics (17)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Abdel G. Babiker ORCID,Cavan Reilly ORCID,Jason V. Baker ORCID,Lianne Siegel ORCID,Jiayi Hu ORCID

Live enrichment

PubMed:41551575 PMC:PMC12809130 OpenAlex:https://openalex.org/W7117120275

National Institutes of Health

Grant: 18X107CF5

UK Research and Innovation Medical Research Council

Grant: MRC_UU_12023/23

CCR NIH HHS

Grant: HHSN261200800001C

NCI NIH HHS

Grant: HHSN261200800001E

National Institute of Allergy and Infectious Diseases

FWCI

0.00

Citation Percentile

0.7%

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.conctc.2025.101592

publisherhttps://doi.org/10.1016/j.conctc.2025.101592

publisherhttps://api.elsevier.com/content/article/PII:S2451865425001668?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2451865425001668?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41551575

Fields of Study

Statistical Methods in Clinical TrialsClinical Laboratory Practices and Quality ControlSARS-CoV-2 detection and testing

Keywords

Type I and type II errorsInterimBonferroni correctionInterim analysisClinical trialCohortSample size determinationAntibodyClinical endpointClinical TrialsMultiple TestingType I Error RateGroup Sequential DesignNested Subgroups

Sustainable Development Goals

SDG 0: Good health and well-being

Type I error control and interim monitoring for co-primary hypotheses involving a subgroup in the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) trial

FAIR Checklist

Authors (5)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)